Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A randomised, single centre, phase IV crossover study to assess the acceptability of once daily Zindaclin® used for one week compared to three other marketed topical antibiotics in patients with mild to moderate acne
ISRCTN ISRCTN43187439
ClinicalTrials.gov identifier
Public title A randomised, single centre, phase IV crossover study to assess the acceptability of once daily Zindaclin® used for one week compared to three other marketed topical antibiotics in patients with mild to moderate acne
Scientific title
Acronym N/A
Serial number at source ZCG/38/C
Study hypothesis To assess the patient acceptability of Zindaclin® when compared to other marketed topical antibiotics.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised active controlled crossover group trial
Countries of recruitment United Kingdom
Disease/condition/study domain Mild to moderate acne vulgaris.
Participants - inclusion criteria Male and female patients aged between 16 and 40 years with mild to moderate acne graded between 1.0 and 7.0 on the Leeds Revised Acne Grading System, 1998.
Participants - exclusion criteria 1. Patients with acne conglobata, acne fulminans, sandpaper acne, submarine comedonal acne or secondary acne were excluded
2. The use of topical or systemic antibiotics or topical antimicrobials within the previous week was disallowed
Anticipated start date 20/02/2002
Anticipated end date 09/10/2002
Status of trial Completed
Patient information material
Target number of participants 65
Interventions 1. Zindaclin® once daily
2. Benzamycin® twice daily
3. Zineryt® twice daily
4. Dalacin-T® Topical Lotion twice daily
Primary outcome measure(s) Patient Acceptability Questionnaire assessing the four study products.
Secondary outcome measure(s) 1. A conjoint analysis assessment of product preferences
2. The level of product use
Sources of funding ProStrakan Pharmaceuticals (UK)
Trial website
Publications
Contact name Dr  Norma  Kellett
  Address Inveresk Research International
Elphinstone Research Centre
  City/town Tranent
  Zip/Postcode EH33 2NE
  Country United Kingdom
Sponsor ProStrakan Pharmaceuticals (UK)
  Address Buckholm Mill Brae
  City/town Galashiels
  Zip/Postcode TD1 2HB
  Country United Kingdom
  Sponsor website: http://www.prostrakan.com
Date applied 09/09/2005
Last edited 17/09/2009
Date ISRCTN assigned 06/10/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central